Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otelixizumab for New-Onset Type 1 Diabetes
NCT01123083Phase 3Completed
- Sponsor
- GSK
- Start
- May 2010
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of otelixizumab in type 1 diabetes mellitus (T1D), sponsored by GSK. Started May 2010; status: completed.
02
Drugs
otelixizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01123083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01123083.